Michael T Tetzlaff

85PUBLICATIONS
593CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (85)

|Jun 26, 2026
Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.

|Jun 26, 2026
The Imipridone ONC206 Inhibits Tumor Growth and Improves Survival in Patient-Derived Xenograft Models of Uveal Melanoma.

|May 18, 2026
FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma.

|Apr 28, 2026
Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance.

|Apr 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

|Jan 10, 2026
Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier.

Margaux Robert, Satabdi Saha, Nazli Dizman

Pageof 15

Frequent Collaborators

19 joint publications

Jennifer Wargo

18 joint publications

Alexander Lazar

17 joint publications

Hussein Tawbi

17 joint publications

Sapna Patel